Skip to main content
S

Synaura

Synaura specializes in the biosynthesis of human milk oligosaccharides (HMOs) to create baby formula that replicates the nutritional profile of breast milk, addressing the nutritional gap for infants who are not breastfed. By providing high-quality HMO raw materials, the company enhances infant immunity, cognitive development, and gut health, supporting the well-being of families in China.

Founded 202150+ followers
Updated 4 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Infants who are not breastfed may miss out on the unique nutritional benefits provided by human milk oligosaccharides (HMOs), which are naturally present in breast milk and play a crucial role in infant health and development. Traditional infant formulas often lack these essential components, potentially leading to compromised immunity, cognitive development, and gut health in formula-fed infants.

Solution

Synaura specializes in the biosynthesis of HMOs, offering a solution to replicate the nutritional composition of breast milk in infant formula. By providing high-quality HMO raw materials, Synaura enables formula manufacturers to create products that better support infant immunity by enhancing innate immunity, cognitive development, and gut health by acting as a natural intestinal barrier. The company focuses on producing a range of HMOs, including 2'-fucosyllactose (2'-FL), 3-fucosyllactose (3-FL), lactose-N-tetrasaccharides (LNT), lactose-N-neotetrasaccharides (LNnT), 3'-sialic lactose (3'-SL), and 6'-sialic lactose (6'-SL), with a particular emphasis on 2'-FL, which is the most abundant in breast milk.

Target Audience

Synaura's primary customers are infant formula manufacturers seeking to enhance their products with high-quality HMOs, as well as nutrition companies looking for custom solutions and expert services in the field of infant nutrition.

Features

  • Biosynthesis of a variety of HMOs, including 2'-FL, 3-FL, LNT, LNnT, 3'-SL, and 6'-SL.
  • Focus on 2'-FL production, the most abundant HMO in breast milk.
  • HMOs enhance innate immunity in infants.
  • HMOs promote cognitive development.
  • HMOs act as a natural intestinal barrier, promoting healthy gut development.
This profile is AI-generated and may contain inaccuracies.